Company Profile

UbiVac LLC
Profile last edited on: 1/14/19      CAGE: 4GYJ8      UEI: MC47NKBQ8A25

Business Identifier: Immunotherapies to combat cancer.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

18183 SW Boones Ferry Road
Portland, OR 97224
   (503) 292-4066
Location: Single
Congr. District: 01
County: Washington

Public Profile

UbiVac LLC is developing a new cancer vaccine technology based on hormones and enzymes produced by tumor cells. UbiVac is a development stage biotechnology company that is focused on discovering, licensing, improving and commercializing immunotherapy products that safely generate and augment the immune response to vaccines. Preclinical studies document that UbiVac technology is significantly more effective than current ‘gold standard vaccines at inducing tumor regression and increasing survival of tumor-bearing hosts. Based on these data a phase I clinical trial of UbiVac vaccine technology will be initiated in patients with non-small cell lung cancer (NSCLC) in the first quarter of 2008. UbiVac is also exploring the application of this approach to the development of an avain flu vaccine

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 2 NIH $288,718
Project Title: Aluminum Oxide Nanoparticles Conjugated to Antigens Potently Induce Tumor Specifi
2013 2 NIH $3,527,726
Project Title: New Cancer Vaccine Technology Based on DRibbles Produced by Tumor Cells

Key People / Management

  Bernard A Fox -- President & CEO

  Sandra Aung

  Steve Buhaly -- Chief Financial Officer

  Bernard A Fox III -- Chief Operating Officer

  Traci Leigh Hilton -- Vice President of Vaccine Development

  Hong-Ming Hu -- Chief Scientific Officer